Marinus Pharmaceuticals — Investor Presentation (December 2020)
59 slides from Marinus Pharmaceuticals's investor presentation, Dec 7, 2020
Slide 1: Corporate Overview 2020
NASDAQ: MRNS@MarinusPharma Corporate Overview 2020
Slide 2: Safe Harbor Statement
Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding Marinus, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private
Slide 3: Ganaxolone Targets Synaptic & Extrasynaptic GABAA Receptors
Ganaxolone (GNX) Targets Synaptic & Extrasynaptic GABAA Receptors Ganaxolone a positive allosteric GABAA receptor modulator with a well-defined MOA designed to treat patients suffering from epilepsy and neuropsychiatric disorders. GNX is designed to modulate both synaptic and extrasynaptic GABAA rec
Slide 4: Corporate Strategy
Corporate Strategy Evaluation of IV and Oral Opportunities Building Upon Status Epilepticus (SE) Maximizing Value for Orphan Epilepsies Leveraging GNX Molecule Expand clinical opportunities from refractory status epilepticus (RSE) to broader SE market Initiate commercial plan Create a global develop
Slide 5: Ganaxolone Development Pipeline
Ganaxolone Development Pipeline
Slide 6: Status Epilepticus Indication
Status Epilepticus Indication
Slide 7: Status Epilepticus: Definition and Epidemiology
Status Epilepticus (SE): Definition and Epidemiology Background Continuous seizures lasting >5 min SE is the second most common neurologic emergency in the U.S. 1 Heterogenous patient population with various etiologies, including glioblastoma, vascular disease, encephalitis, drug or alcohol withdraw
Slide 8: Goals of a New Therapy for the Treatment of SE
Goals of a New Therapy for the Treatment of SE Established Status Epilepticus (ESE) Refractory Status Epilepticus (RSE) Medically induced Coma Super Refractory Status Epilepticus (SRSE) 1st line2nd line 3rd line Benzodiazepine Administered IV AED’s (antiepileptic drugs) IV GNX IV Anesthetics ©2020 M
Slide 9: Pharmacokinetics/Pharmacodynamics Well Suited for Acute SE Treatment
Pharmacokinetics/Pharmacodynamics Well Suited for Acute SE Treatment Experimental PK – plasma and brain1 Human PD – EEG changes2 Ganaxolone targets the extrasynaptic receptor, is associated with high brain concentrations, and delivers a rapid onset of action Brain and plasma concentration after gana
Slide 10: Phase 2 SE Trial Design
Phase 2 SE Trial Design Evaluate IV ganaxolone in refractory SE patients SE Patients Diagnosis of convulsive or non-convulsive SE Failed at least one 2nd line IV AED but had not progressed to 3rd line IV anesthetics Screening Treatment Period Loading DoseMaintenanceTaper Post-treatment Follow-up 24
Slide 11: Patient Demographics of Phase 2 Trial
Patient Demographics of Phase 2 Trial 17 patients enrolled 8 males, 9 females Mean age: 57 years old (range: 23-88) History of Epilepsy 7 (41%) yes, 10 (59%) no Types of SE 5 (29%) CSE, 11 (65%) NCSE, 1 (6%) CSE→NCSE Mean # of failed first-and-second line IV AEDs (including benzodiazepines) Mean # o
Slide 12: Phase 2 Trial Results Demonstrated Rapid Onset And Durability of Effect
Phase 2 Trial Results Demonstrated Rapid Onset And Durability of Effect Cohort No escalation to IV anesthetics within 24 hours from infusion initiation (Primary Endpoint) Status-free through 24 hours from infusion initiation (investigator determination) No escalation to additional IV AEDs or IV anes
Slide 13: PK/PD Relationship and Rationale for Target Dose
PK/PD Relationship and Rationale for Target Dose Modeled PK Curves for All Dose Groups Seizure Burden Reduction Occurred Rapidly in All Dose Groups High Dose Achieves Target Range ≥ 500 ng/mL for ~8 hoursOnly High Dose Provided Sustained Reduction (>80%) Throughout Entire Analysis Window Data presen
Slide 14: IV Ganaxolone Safety Summary
IV Ganaxolone Safety Summary 10 SAEs in 6 patients (also included in AEs) 50 AEs in 16 patients 2 related in 2 patients 2 severe sedation 8 non-related in 4 patients 1 Death due to withdrawal of life support 1 Respiratory depression 1 Bowel perforation (fatal) 1 Sepsis (fatal) 1 Fall 1 Loss of consc
Slide 15: Overview of U.S. Phase 3 RSE RAISE Trial Design
Overview of U.S. Phase 3 RSE RAISE Trial Design Trial design•Randomized, placebo-controlled (adjunctive to standard-of-care) clinical trial Target patient population•Status epilepticus patients (n=124) who have failed benzodiazepines and ≥ 2 IV AEDs Dosing 36-hour infusion followed by a 12-hour tape
Slide 16: RSE Phase 3 RAISE Clinical Planning
RSE Phase 3 RAISE Clinical Planning Treatment PeriodFollow-up Period Initiation Status Site identification through initiation underway Drug and placebo supply ready for shipment to sites Daily S CHours 0 -24 Day 2 Hours 24-36 Hours 36-48 Daily hours Weeks 1,2,3 & 4 Currently recruiting patients R EB
Slide 17: RAISE Trial Sites Standard of Care Progression to IV Anesthesia
RAISE Trial Sites Standard of Care Progression to IV Anesthesia Surveyed PI’s at selected RAISE Trial sites to learn more about their standard of care natural history progression to IV anesthesia following the failure of one versus more than one 2nd-line IV AEDs 100 %of Patients Progressing to 3rd-l
Slide 18: BARDA Contract – Refractory Status Epilepticus
BARDA Contract – Refractory Status Epilepticus Key Contract Parameters BARDA to contribute $21 million in base contract to support the Phase 3 RAISE clinical trial in RSE and preclinical studies of ganaxolone in nerve agent exposure animal models. BARDA may contribute up to an additional $30 million
Slide 19: Commercial Opportunity
Commercial Opportunity M’ARINUS PHARMACEUTICALS
Slide 20: Quantifying the Significant Clinical and Economic Burden of RSE
Quantifying the Significant Clinical and Economic Burden of RSE The Phase 3 trial of ganaxolone in refractory SE aims to demonstrate rapid onset of action capable of preventing escalation to IV anesthetics. Treatment with IV anesthetics has been reported to lead to increased length of hospital admis
Slide 21: RSE is a Neurological Emergency With Significant Unmet Need
RSE is a Neurological Emergency With Significant Unmet Need in a Severely Impaired and Costly Patient Population Utilization and Cost Outcomes Metric Cohort 1 (≤ 1 IV AED) Cohort 2 (> 1 IV AED) Cohort 3 (≥ 1 IV anesthetic) All Unique RSE patient encounter, N (%) 14,694 (33.4) 10,140 (23.1) 19,154 (4
Slide 22: Potential Launch Into the Hospital Setting
Potential Launch Into the Hospital Setting Designed to be Driven by Data, Customer Collaboration & Protocolization of Ganaxolone in RSE Critical Success Factors for RSE Launch Clinical and Economic Evidence Society Guideline & Account Access Experienced Hospital Sales • Ph3 data to support clinical
Slide 23: Additional Commercial Opportunities Along SE Continuum
Additional Commercial Opportunities Along SE Continuum Potential to leverage existing hospital sales force to address > 3x patient population in ESE & SRSE ESETT DeLorenzo RJ Pellock JM Towne AR Boggs JG. Epidemiology of status epilepticus. J Clin Neurophysiol. 1995; 12: 316-325 ©2020 Marinus Pharma
Slide 24: Potential Expansion of Ganaxolone into Established Status Epilepticus
Potential Expansion of Ganaxolone into Established Status Epilepticus (ESE) Emergency RoomICU Tertiary Center ICU Unique Environment: -No EEG -Risk of rapid escalation of care -Convulsive patients: new dosing paradigm – bolus and short infusion time (2-24 hours)
Slide 25: Established Status Epilepticus – Use of Ganaxolone in Emergency Room
Established Status Epilepticus – Use of Ganaxolone in Emergency Room Pilot: N = 4-5 per cohort Failed benzodiazepine Open bolusIV ganaxolone infusion Standard of care IV AED Blinded: N = 40 per arm Failed benzodiazepine 1:1 bolus Placebo bolus IV ganaxolone: Placebo Standard of care IV AED Screening
Slide 26: Genetic Epilepsy Franchise
Genetic Epilepsy Franchise
Slide 27: CDKL5 Deficiency Disorder
CDKLS Deficiency Disorder M’ARINUS PHARMACEUTICALS
Slide 28: CDKL5 Deficiency Disorder (CDD)
CDKL5 Deficiency Disorder (CDD) Cause Mutation of the cyclin-dependent kinase-like 5 (CDKL5) gene, located on the X chromosome Symptoms Early-onset, treatment refractory seizures, & severe neuro-developmental delay Most can’t walk, talk or care for themselves Suffer from scoliosis, visual impairment
Slide 29: Global Phase 3 Pivotal Trial Design
Global Phase 3 Pivotal Trial Design Historical Control 8 weeks Baseline 6 weeks Titration 4 weeks Maintenance 13 weeks Titration 4 weeks Open-Label Phase Double-Blind PhaseOpen-Label Phase Trial Details Evaluated the use of oral ganaxolone in children and young adults Global, double-blind, placebo-c
Slide 30: Subject Baseline Clinical Characteristics & Prior/Concomitant Medications
Subject Baseline Clinical Characteristics & Prior/Concomitant Medications Baseline seizure burden and AED history highlights unmet need
Slide 31: Ganaxolone Achieved Primary Efficacy Endpoint in Seizure Reduction
Ganaxolone Achieved Primary Efficacy Endpoint in Seizure Reduction and Secondary Endpoint in Caregiver Impression of Change Median Percent Reduction 28-day Frequency of Major Motor Seizures = 29.7%* p = 0.002** Caregiver Global Impression of Change in Seizure Intensity / Duration (CGI-CSID) 3032.2%
Slide 32: Marigold Cumulative Response Curve
Marigold Cumulative Response Curve ** ** *p < 0.05 * * * * * Ganaxolone Placebo % of Patients 40 20 0 50 *Fisher's Exact Test % Reduction in Major Motor Seizure Frequency
Slide 33: Consistent Efficacy Signal Across the Broader CDD Population
Consistent Efficacy Signal Across the Broader CDD Population Ganaxolone demonstrated a similar efficacy signal across multiple subgroups related to baseline demographics and seizure frequency. –Supports beneficial effect in the U.S. patient population Percent Reduct ion in M edian M ajor M ot or Sei
Slide 34: Phase 3 Safety Summary
Phase 3 Safety Summary Treatment Emergent Adverse Events (TEAE) Serious Treatment Emergent Adverse Events Preferred Term Placebo (n=51) Ganaxolone (n=50) Any Serious TEAE, n (%) 5 (9.8) 6 (12.0) Bronchitis 0 (0.0) 1 (2.0) Rhinovirus Infection 0 (0.0) 1 (2.0) Urinary Tract Infection 0 (0.0) 1 (2.0) P
Slide 35: Durable Seizure Improvements in the Open Label Extension
Ganaxolone’s Potential to Provide Durable Seizure Improvements in the Open Label Extension Seizures associated with CDD are often refractory to treatment with existing AEDs and improvements may be short-lived (<3 months)1 Preliminary analysis* of the open-label extension (OLE) provides insights into
Slide 36: Average Ganaxolone Levels Correlate with Seizure Reduction
Average Ganaxolone Levels Correlate with Seizure Reduction Logarithms of plasma GNX level and percentage change in major motor seizure frequency were negatively correlated Patients in the Medium and High GNX level groups had an average GNX concentration of 120 ng/mL and a median 43% reduction in sei
Slide 37: Efforts to Improve Ganaxolone Exposure in Chronic Epilepsies
Efforts to Improve Ganaxolone Exposure in Chronic Epilepsies Dosing regimen: Marigold Study was the first Phase 3 study of ganaxolone to evaluate three times a day (TID) dosing Predicted pharmacokinetic (PK) curves for TID and two times a day (BID) dosing demonstrate increase trough GNX levels which
Slide 38: Ganaxolone Formulation Work in Progress for Second Generation Candidate
Ganaxolone Formulation Work in Progress for Second Generation Candidate Exploring opportunities to improve bioavailability and PK profile Potential expansion into new indications and into new therapeutic areas Targeting IV-to-oral step down for patients that may benefit from continued therapy IV Dos
Slide 39: Tuberous Sclerosis Complex
Tuberous Sclerosis Complex M’ARINUS PHARMACEUTICALS
Slide 40: Allo-S as Potential Biomarker Across Various Genetic Epilepsies
Allo-S as Potential Biomarker Across Various Genetic Epilepsies Scientific literature associates genetic orphan epilepsies with neurosteroid imbalances Marinus has identified abnormal neurosteroid levels in several patient subtypes These findings lead to stratification by Allo-S biomarker in clinica
Slide 41: Tuberous Sclerosis Complex
Tuberous Sclerosis Complex CauseDefect or mutation of TSC1 and/or TSC2 genes Symptoms abnormalities Prevalence~25K-40K refractory TSC patients in the U.S.* TreatmentsLimited approved treatments Mechanistic RationalePotential neurosteroid deficiency1 1 diMichele, et al, J. Neuro Neurosurg Psychiatry,
Slide 42: Unmet Need in TSC Epilepsy and Scientific Rationale for Ganaxolone
Unmet Need in TSC Epilepsy and Scientific Rationale for Ganaxolone Epilepsy present in ~90% of individuals affected with TSC Existing treatments fail to control seizures in ~60% of individuals with TSC-associated epilepsy Uncontrolled seizures, especially early in life, may lead to developmental del
Slide 43: Phase 2 TSC Trial Design
PART A Base (4 Weeks) GNX Titration (4 Weeks) GNX Maintenance (8 Weeks) Baseline Period PART B Open-Label Extension (OLE) (24 Weeks) * Available to patients that respond to GNX as defined per protocol OLE Period 2-week taper upon GNX discontinuation Screening Visit Baseline Treatment Visit (if not c
Slide 44: PCDH19 Related Epilepsy
PCDH19 Related Epilepsy
Slide 45: PCDH19-Related Epilepsy
PCDH19-Related Epilepsy CauseInherited mutation of protocadherin 19 (PCDH19) gene. Located on X chromosome Symptoms Early-onset seizures, cognitive and sensory impairment, and psychiatric and behavioral disorders. Seizures last from days to weeks; sensitive to fever Prevalence Affects ~10K children
Slide 46: Seizure Reduction Observed in PCDH19-RE Phase 2 Trial
Seizure Reduction Observed in PCDH19-RE Phase 2 Trial in Patients with Low Allo Levels 25% decrease in median seizure frequency reported in Phase 2 (n=11) Stratification of patients by baseline plasma Allo levels identifies a subpopulation with expected improved efficacy on GNX When comparing seizur
Slide 47: Biomarker Stratified Proof of Concept Study in PCDH19
Biomarker Stratified Proof of Concept (POC) Study in PCDH19 Primary efficacy analyses will be conducted using this cohort PCDH19 (all-patients) n~20-22 Low Allo-S Biomarker + High Allo-S Biomarker - R 1:1 R 1:1 Placebo Ganaxolone Up to 600 mg 3x/day Placebo Ganaxolone Up to 600 mg 3x/day Ganaxolone
Slide 48: Commercial Opportunity
Commercial Opportunity M’ARINUS PHARMACEUTICALS
Slide 49: Commercialization Preparedness
Commercialization Preparedness Executing research with Payers and Physicians around TPP / Value Proposition Identifying organizational needs for field resources, systems and processes Developing plans to scale up Advocacy, Scientific Affairs and Commercial teams Readying supply chain to support pack
Slide 50: Our Oral Franchise Model is Driven by Ganaxolone Scientific Rationale
Our Oral Franchise Model is Driven by Ganaxolone Scientific Rationale and Unmet Need in Debilitating Rare Epilepsy Disorders Given CDKL5 and TSC patient seizure burden, overlap of CDKL5 and TSC prescribers, and common market dynamics, we group both indications under a franchise go to market CDKL5 De
Slide 51: Our Goal: Build a Sustainable Franchise in Rare Epilepsy
Our Goal: Build a Sustainable Franchise in Rare Epilepsy Opportunity to expand treated population through future clinical development Phase 2 (TSC) 40,000 patients2 Rare Epilepsy ~163,0005 Phase 3 (CDKL 5) ~5,500 patients1 80-90% refractory3 50-60% refractory3 20-40% refractory4 ~ 4,400 CDKL 5 Patie
Slide 52: Key Findings from Recently Conducted Market Research
Key Findings from Recently Conducted Market Research Show that Ganaxolone is Well Suited for Broad Clinical Adoption Across Indications Mechanism of Action Ganaxolone’s extrasynaptic mechanism of action well understood and viewed as differentiable TPP Reactions Many HCPs are excited about the opport
Slide 53: Intellectual Property
Intellectual Property
Slide 54: Multiple Layers Of Potential Protection
Multiple Layers Of Potential Protection Orphan drug designations for CDD and PCDH19 provide 7 and 10 years regulatory exclusivity in US and EU, respectively. Orphan drug designation for SE provides 7 years regulatory exclusivity in US.
Slide 55: Thank You
NASDAQ: MRNS@MarinusPharma Thank You
Slide 56: Appendix
Appendix M'ARINUS PHARMACEUTICALS
Slide 57: Details on Baseline Patient Characteristics for Phase 2 SE Trial
Details on Baseline Patient Characteristics for Phase 2 SE Trial 1 Low Vascular No NCSE LAC, LEV 200mg (200-600mg) 2 Low Unknown Yes NCSE fPHT, LEV 1,000mg (1000-3000mg) 3 Low Vascular No NCSE LOR, LAC, LEV 600mg (200-600mg) 4 Low Vascular No NCSE LOR, LAC, LEV 600mg (200-600mg) 5 Low Tumor No CSE L
Slide 58: Subject Baseline Demographics & Country Enrollment in Marigold Study
Subject Baseline Demographics & Country Enrollment in Marigold Study (CDD) Demographic Placebo (n=51) Ganaxolone (n=50) Total (n=101) Age, median 7.0 5.0 6.0 Gender, n (%) Male 10 (19.6) 11 (22.0) 21 (20.8) Female 41 (80.4) 39 (78.0) 80 (79.2) Ethnicity, n (%) Hispanic or Latino 6 (11.8) 4 (8.0) 10
Slide 59: Responder Analysis – Marigold Study
Responder Analysis – Marigold Study 100 % of Patients p=0.001* 6057.1% Ganaxolone Placebo Percent Reductions in Major Motor Seizure Frequency 40p=0.064* 23.5%24.5% 20 9.8%10.2% 0 3.9% 75% *Fisher's Exact Test Reduction in Major Motor Seizure Frequency
Marinus Pharmaceuticals — Investor Presentation (December 2020) on 6ix